California Gov. Jerry Brown vetoed a bill that would limit the use of biosimilars by requiring pharmacists to notify doctors and patients if a biosimilar was being substituted for the prescribed drug, which the bill said could be done in cases in which the FDA says the biosimilar is interchangeable with the brand-name drug. "This requirement, which on its face looks reasonable, is for some reason highly controversial," Brown's veto message said. A notification requirement was premature because the FDA has yet to decide on the standards for the biosimilars' interchangeability with the original products, Brown said.

Related Summaries